Literature DB >> 27238708

Human extravillous trophoblasts bind but do not internalize antiphospholipid antibodies.

Chez A Viall1, Qi Chen2, Peter R Stone3, Lawrence W Chamley3.   

Abstract

INTRODUCTION: Obstetric morbidity in women with antiphospholipid antibodies (aPLs) may reflect the adverse effects of aPLs on placental cells such as extravillous trophoblasts and the syncytiotrophoblast. Antiphospholipid antibodies may affect the syncytiotrophoblast after being internalised by members of the Low-density lipoprotein receptor (LDLR) family and the antigen of aPLs, β2 glycoprotein I. AIM: This study aimed to determine whether aPL internalization was a mechanism by which aPLs adversely affect extravillous trophoblasts.
METHOD: of STUDY: Fluorescently-labelled monoclonal aPLs IIC5 or ID2 were incubated with first trimester extravillous trophoblast outgrowths and visualized by microscopy. The subcellular expression of β2 glycoprotein I and LDLR family members was investigated by live/permeabilised immunocytochemistry.
RESULTS: Unlike the syncytiotrophoblast of anchoring villi, monoclonal aPLs were not internalised by extravillous trophoblasts, which expressed LDLR family members intracellularly. The aPL IIC5 bound to the surface of extravillous trophoblasts in a pattern similar to the extracellular expression of β2 glycoprotein I.
CONCLUSIONS: The mechanisms of action of aPLs are different in extravillous trophoblasts and the syncytiotrophoblast. The interaction of aPLs with the extravillous trophoblast surface, which may involve β2 glycoprotein I, is consistent with reports that aPLs trigger intracellular signaling cascades through cell-surface receptors.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antiphospholipid antibody; Extravillous trophoblast; Placenta; Pregnancy

Mesh:

Substances:

Year:  2016        PMID: 27238708     DOI: 10.1016/j.placenta.2016.03.011

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  7 in total

Review 1.  Emerging Treatment Models in Rheumatology: Antiphospholipid Syndrome and Pregnancy: Pathogenesis to Translation.

Authors:  Vikki M Abrahams; Lawrence W Chamley; Jane E Salmon
Journal:  Arthritis Rheumatol       Date:  2017-07-18       Impact factor: 10.995

2.  Low molecular weight heparin and aspirin exacerbate human endometrial endothelial cell responses to antiphospholipid antibodies.

Authors:  Zola Chihombori Quao; Mancy Tong; Elena Bryce; Seth Guller; Lawrence W Chamley; Vikki M Abrahams
Journal:  Am J Reprod Immunol       Date:  2017-11-14       Impact factor: 3.886

3.  Antiphospholipid Antibodies Inhibit Trophoblast Toll-Like Receptor and Inflammasome Negative Regulators.

Authors:  Melissa J Mulla; Ingrid C Weel; Julie A Potter; Stefan M Gysler; Jane E Salmon; Maria T S Peraçoli; Carla V Rothlin; Lawrence W Chamley; Vikki M Abrahams
Journal:  Arthritis Rheumatol       Date:  2018-04-25       Impact factor: 10.995

Review 4.  Obstetric Anti-phospholipid Syndrome: State of the Art.

Authors:  Maria Chiara Gerardi; Melissa Alexandre Fernandes; Angela Tincani; Laura Andreoli
Journal:  Curr Rheumatol Rep       Date:  2018-08-13       Impact factor: 4.592

5.  Antiphospholipid Antibodies Increase Endometrial Stromal Cell Decidualization, Senescence, and Inflammation via Toll-like Receptor 4, Reactive Oxygen Species, and p38 MAPK Signaling.

Authors:  Mancy Tong; Teimur Kayani; Deidre M Jones; Jane E Salmon; Shannon Whirledge; Lawrence W Chamley; Vikki M Abrahams
Journal:  Arthritis Rheumatol       Date:  2022-04-27       Impact factor: 15.483

6.  Antiphospholipid antibodies increase the levels of mitochondrial DNA in placental extracellular vesicles: Alarmin-g for preeclampsia.

Authors:  Mancy Tong; Caroline Johansson; Fengyi Xiao; Peter R Stone; Joanna L James; Qi Chen; Lynsey M Cree; Lawrence W Chamley
Journal:  Sci Rep       Date:  2017-11-29       Impact factor: 4.379

Review 7.  Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review.

Authors:  Jaume Alijotas-Reig; Enrique Esteve-Valverde; Ariadna Anunciación-Llunell; Joana Marques-Soares; Josep Pardos-Gea; Francesc Miró-Mur
Journal:  J Clin Med       Date:  2022-01-28       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.